Production of antibodies and antibody fragments containing non-natural amino acids in Escherichia coli

Production of antibodies and antibody fragments containing non-natural amino acids in Escherichia coli

Therapeutic bioconjugates are emerging as an essential tool to combat human disease. Site-specific conjugation technologies are widely recognized as the optimal approach for producing homogeneous drug products. Non-natural amino acid (nnAA) incorporation allows the introduction of bioconjugation han...

Full description

Saved in:

Bibliographic Details
Main Authors:	Jacquelyn Blake-Hedges, Dan Groff, Wilson Foo, Jeffrey Hanson, Elenor Castillo, Miao Wen, Diana Cheung, Mary Rose Masikat, Jian Lu, Young Park, Nina Abi Carlos, Hans Usman, Kevin Fong, Abigail Yu, Sihong Zhou, Joyce Kwong, Cuong Tran, Xiaofan Li, Dawei Yuan, Trevor Hallam, Gang Yin
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2024-12-01
Series:	mAbs
Subjects:	Antibody–drug conjugate bioconjugation e. coli expression non-natural amino acid site-specific therapeutic protein
Online Access:	https://www.tandfonline.com/doi/10.1080/19420862.2024.2316872
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Comparative Assessment of Gold Nanoparticle–Antibody Conjugates with Two Differently Shaped Particles for Multimodal Colorimetric Lateral Flow Assay
by: Vinayak Sharma, et al.
Published: (2024-03-01)

Application of two novel anionic peroxidases from Raphanus sativus L. var niger roots in labeling antibodies and developing an enzyme-linked immunosorbent assay
by: Hooman Askari, et al.
Published: (2025-01-01)

Target Bioconjugation of Protein Through Chemical, Molecular Dynamics, and Artificial Intelligence Approaches
by: Sk Jahir Abbas, et al.
Published: (2024-12-01)

Chemo-selective modification of cysteine residue: synthesis and application in the discovery of potential drug candidates
by: Yanyan Liao, et al.
Published: (2024-09-01)

Biomimetic peptide conjugates as emerging strategies for controlled release from protein-based materials
by: Juthatip Manissorn, et al.
Published: (2025-12-01)

New Steroid–Alkaloid Bioconjugates as Potential Bioactive Compounds: Synthesis, Spectroscopic and In Silico Study
by: Hanna Koenig, et al.
Published: (2025-01-01)

Antibody drug conjugates in the clinic
by: Edidiong Udofa, et al.
Published: (2024-11-01)

Tyrosine bioconjugation using stably preparable urazole radicals
by: Shinichi Sato, et al.
Published: (2024-12-01)

Current issues with antibody-conjugated lipid nanoparticles
by: Aayush
Published: (2025-02-01)

Clinical advances in antibody-drug conjugates for hematological malignancies
by: TANG Sijie, et al.
Published: (2024-12-01)

The challenges to develop antibody-conjugated nanomedicine products
by: Liwei Hui, et al.
Published: (2023-12-01)

Guanidines Conjugated with Cell-Penetrating Peptides: A New Approach for the Development of Antileishmanial Molecules
by: João Victor Marcelino de Souza, et al.
Published: (2025-01-01)

Improved targeting of an anti‐TAG‐72 antibody drug conjugate for the treatment of ovarian cancer
by: Megan Minnix, et al.
Published: (2020-07-01)

The Antibody Drug Conjugate, Belantamab-Mafodotin, in the Treatment of Multiple Myeloma: A Comprehensive Review
by: Almodovar Diaz AA, et al.
Published: (2024-12-01)

Biparatopic antibodies: therapeutic applications and prospects
by: David L. Niquille, et al.
Published: (2024-12-01)

Six events that shaped antibody approvals in oncology
by: Suman Paul, et al.
Published: (2025-02-01)

Antibody–Drug Conjugates: A Start of a New Era in Gynecological Cancers
by: Samir Fasih, et al.
Published: (2024-11-01)

Key considerations based on pharmacokinetic/pharmacodynamic in the design of antibody-drug conjugates
by: Yangyang Gao, et al.
Published: (2025-01-01)

Online native hydrophobic interaction chromatography-mass spectrometry of antibody-drug conjugates
by: Trevor Kempen, et al.
Published: (2025-12-01)

Unlocking the Potential of Hydroxycinnamic Acid Bioconjugates: Tailored Derivatives for Biomedical, Cosmetic, and Food Applications
by: José C. J. M. D. S. Menezes, et al.
Published: (2024-10-01)

Maytansinoids in cancer therapy: advancements in antibody–drug conjugates and nanotechnology-enhanced drug delivery systems
by: Matteo Perra, et al.
Published: (2025-01-01)

Discovery of a novel highly specific, fully human PSCA antibody and its application as an antibody-drug conjugate in prostate cancer
by: Xiaojie Chu, et al.
Published: (2024-12-01)

1.4 nm gold nanoparticle-antibody conjugates for in situ gold immunolabelling after transduction into living human cells
by: Groysbeck, Nadja, et al.
Published: (2023-10-01)

Impact of HER2-targeting antibody drug conjugates in treatment strategies for patients with breast cancer
by: Hanghang Ma, et al.
Published: (2025-02-01)

Ocular adverse events associated with antibody-drug conjugates: a comprehensive pharmacovigilance analysis
by: Heng Chen, et al.
Published: (2024-12-01)

Impacts of genomic alterations on the efficacy of HER2-targeted antibody–drug conjugates in patients with metastatic breast cancer
by: Riqing Huang, et al.
Published: (2025-01-01)

Labeling tumor-associated extracellular vesicles with antibody-DNA conjugates for quantitative analysis
by: Xiao Du, et al.
Published: (2025-01-01)

T cell receptor-directed antibody-drug conjugates for the treatment of T cell-derived cancers
by: Katrin Schoenfeld, et al.
Published: (2024-09-01)

Enhancing the efficacy of near-infrared photoimmunotherapy through intratumoural delivery of CD44–targeting antibody–photoabsorber conjugatesResearch in context
by: Yuichi Adachi, et al.
Published: (2025-02-01)

Facilitating high throughput bispecific antibody production and potential applications within biopharmaceutical discovery workflows
by: Caitlin Fawcett, et al.
Published: (2024-12-01)

Antibody-epitope conjugates deliver immunogenic T-cell epitopes more efficiently when close to cell surfaces
by: W. van der Wulp, et al.
Published: (2024-12-01)

Targeted protein degradation through site-specific antibody conjugation with mannose 6-phosphate glycan
by: Kaori Mukai, et al.
Published: (2024-12-01)

A bispecific antibody-drug conjugate targeting pCAD and CDH17 has antitumor activity and improved tumor-specificity
by: Alyssa Synan, et al.
Published: (2025-12-01)

Utility of 131I-HLX58-Der for the Precision Treatment: Evaluation of a Preclinical Radio-Antibody-Drug-Conjugate Approach in Mouse Models
by: Liu Y, et al.
Published: (2025-01-01)

Unveiling the future of breast cancer therapy: Cutting-edge antibody-drug conjugate strategies and clinical outcomes
by: Lu Sun, et al.
Published: (2024-12-01)

Near-infrared duocarmycin photorelease from a Treg-targeted antibody-drug conjugate improves efficacy of PD-1 blockade in syngeneic murine tumor models
by: Hiroshi Fukushima, et al.
Published: (2024-12-01)

A phase Ia study of a novel anti-HER2 antibody–drug conjugate GQ1001 in patients with previously treated HER2 positive advanced solid tumors
by: Chenfei Zhou, et al.
Published: (2025-01-01)

Research Progress and Perspectives of Antibody-drug Conjugates Targeting Trophoblast Cell Surface Antigen-2 in Advanced Non-small Cell Lung Cancer
by: Jingyan XU, et al.
Published: (2024-10-01)

The Efficacy and Safety of Folate Receptor α‐Targeted Antibody‐Drug Conjugate Therapy in Patients With High‐Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers: A Systematic Review and Meta‐Analysis
by: Eun Taeg Kim, et al.
Published: (2024-11-01)

Multi-environment and multi-parameter screening of stability and coating efficiency of gold nanoparticle bioconjugates in application media
by: Junjie Wang, et al.
Published: (2024-12-01)